APR 25, 2016 04:00 AM PDT

Big drop in cervical cancer if U.S. adopted new HPV vaccine

A new vaccine for human papillomavirus (HPV) would significantly reduce both cervical cancer incidence and health care costs if states coordinated policies to improve coverage, a new analysis shows.
 
The CDC currently recommends vaccination for females aged 11-26 and males aged 11-21. Three doses are recommended for lasting protection against cervical cancer. HPV is common in both males and females, and can cause cancers of the anus, mouth/throat, and penis in males.

HPV, the most common sexually transmitted infection in the United States, is the primary cause of cervical cancer. Gardasil 9, a new vaccine available since 2015, provides protection against nine different HPV types, including five cancer-causing ones not included in older vaccines.

For a new study published in the Proceedings of the National Academy of Sciences, researchers developed a transmission model to determine the potential impact of the vaccine on cervical cancer incidence and health care costs.

The new model took into account several factors affecting HPV transmission and cervical cancer progression and incorporated 10 HPV types, demographics, age, sexual behavior, and state-specific vaccine policies and migration patterns.

The findings show that switching to Gardasil 9 would result in greater health benefits at the same or lower cost. Specifically, the new vaccine would decrease cervical cancer incidence by 73 percent, compared to 63 percent with the older vaccines, and reduce mortality by 49 percent versus 43 percent.

Further, the improvements could be realized at the same or lower cost despite the higher per-dose cost of Gardasil 9. Notably, the finding of increased cost-effectiveness holds whether vaccination rates increase or stay the same, says first author David Durham, associate research scientist at the Center for Infectious Disease Modeling and Analysis (CIDMA) at the Yale School of Public Health. “Adopting the new vaccine is always cost-effective relative to the old vaccines.”
 

More bang for the buck


In addition, efforts to expand HPV vaccination, particularly in states with low coverage, could prevent even more cancers and deaths, researchers say, adding that due to interstate migration, all states would benefit if they aligned vaccination policy.

“The greatest benefits of HPV vaccination both in terms of cancer reduction and health care costs are realized when policy promoting vaccination is coordinated across states,” says Alison Galvani, professor of epidemiology and director of CIDMA.

Furthermore, increased funding to states could improve vaccine coverage and public health. Durham pointed to funds provided by states and the Centers for Disease Control and Prevention’s (CDC) Prevention and Public Health Fund.

More resources “do lead to improvements in coverage. In terms of number of cancers averted per vaccine, there are decreasing marginal returns in states that already have high coverage. You get more bang for your buck by focusing first on states with lower coverage.”

The CDC currently recommends vaccination for females aged 11-26 and males aged 11-21. Three doses are recommended for lasting protection against cervical cancer. HPV is common in both males and females, and can cause cancers of the anus, mouth/throat, and penis in males.

The National Institutes of Health, the James S. McDonnell Foundation, and the Canadian Institutes of Health Research funded the work.

Source: Yale University

This article was originally published on futurity.org.
About the Author
  • Futurity features the latest discoveries by scientists at top research universities in the US, UK, Canada, Europe, Asia, and Australia. The nonprofit site, which launched in 2009, is supported solely by its university partners (listed below) in an effort to share research news directly with the public.
You May Also Like
MAY 17, 2018
Immunology
MAY 17, 2018
Epigenetic Similarities Between Rheumatoid Arthritis and Huntington's Disease
A detailed investigation into the epigenome of rheumatoid arthritis (RA) patients revealed unexpected similarities between RA and Huntington’s diseas...
MAY 23, 2018
Immunology
MAY 23, 2018
Isolating The Source of Interleukin-25 In Common Respiratory Disorders
The latest discovery from the Perelman School of Medicine at the University of Pennsylvania examined the mechanisms behind how the immune system responds t...
JUN 12, 2018
Cancer
JUN 12, 2018
CD44 Insights & Cancer Influence
CD44 is a known cell surface protein involved in numerous interactions; it is overexpressed in cancerous tissue and its isoforms are being investigated as targets for cancer immunotherapy...
JUL 04, 2018
Microbiology
JUL 04, 2018
Revealing How Gut Bacteria can Impact our Health
Our GI tract pays host to trillions of microbes, which have been shown to play a highly influential role in our health and well-being....
AUG 06, 2018
Immunology
AUG 06, 2018
Maternal Dengue Immunity Protects Against Infant Zika Infection
Maternal Dengue immunity produces CD8+ T cells that protect against fetal Zika infection preventing zika-related malformations....
AUG 20, 2018
Immunology
AUG 20, 2018
Photosensitivity Linked to Immune Cell Dysfunction
The Langerhans cells of the immune system activate cytokines essential for skin protection when exposed to UV that is functional in photosensitive individuals....
Loading Comments...